MedTrace Logo

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

NCT01684163 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 369

Last updated 2016-03-17

No results posted yet for this study

Summary

GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another antidepressant drug that the patient is already taking.

Conditions

Interventions

DRUG

GLYX-13 5 mg/kg

Intravenous administration of 5 mg/kg into arm.

DRUG

GLYX-13 10 mg/kg

Intravenous administration of 10 mg/kg into arm.

DRUG

Placebo

Intravenous administration of normal saline into arm.

Sponsors & Collaborators

  • Naurex, Inc, an affiliate of Allergan plc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Naurex Inc, an affilate of Allergan plc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-04-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01684163 on ClinicalTrials.gov